BI and Ciulli's lab have developed ACBI3 (PROTAC) that has shown to be able to eliminate 13 out of the 17 most common KRAS mutants with high potency and selectivity. "KRAS degradation by ACBI3 was also more efficacious than using KRAS small molecule inhibition, and induced effective tumour regression in mouse models, validating KRAS degradation as a novel therapeutic concept" just published in Science https://buff.ly/3Xzmriu
Experts from our Centre for Targeted Protein Degradation, working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug, a “protein degrader”. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving outcomes for all patients with cancers caused by KRAS mutations. The findings have been published in the reputed journal, Science.
